Rouen, France, May 21, 2019 - Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, announces today that Pr Haude, Dr Lorgat and Pr Nef have joined its medical advisory board. All are global experts and recognized leaders in interventional cardiology.
The board plays a key role in defining the clinical strategy of the company. Their clinical work will contribute to the worldwide growth of robotics in interventional cardiology.
Philippe Bencteux, president and founder of Robocath, said: “I’m particularly proud and pleased to welcome Pr. Michael Haude, Dr. Faizel Lorgat and Pr. Holger Nef to our medical advisory board (MAB). As experts they have demonstrated their strong commitment and enthusiasm to being part of this new page in history. We all share the same vision regarding the future of interventional cardiology and the key role that our robotic platform will play in this field.”
The new appointees are:
Pr. Michael Haude - Städtische Kliniken Neuss – Neuss, Germany
Head of the cardiac catheterization laboratory at the Neuss Clinic for the last 25 years, past chairman of the Working Group on Interventional Cardiology (AGIK) at the German Society of Cardiology, PCR and ESC board member and EAPCI president from 2016 to 2018. Currently an EAPCI board member, Pr. Haude has published more than 300 scientific articles.
“I’m very proud to be involved in the very first steps in robotics in Europe and to initiate clinical research in Germany in this important new innovation in interventional cardiology.”
Dr. Faizel Lorgat - Netcare Christiaan Barnard Memorial Hospital - Cape Town, South Africa
Interventional cardiologist at Christiaan Barnard Memorial Hospital since 1998. One of the first users of a robotic system for electrophysiology, Dr. Lorgat has performed more than 1,600 procedures with this robotic assistance over a period of 6 years and is an active research contributor in this field.
Pr. Holger Nef - Giessen University Hospital – Giessen, Germany
Head of the cardiac catheterization laboratory at Giessen University Hospital for the last 10 years. Director of the department for structural heart disease at the Herz-Kreislauf-Zentrum, Rotenburg, Germany. President of the Working Group on Interventional Cardiology (AGIK) at the German Society of Cardiology since 2015, Pr. Nef is the author of numerous scientific publications and plays an active role in professional education.
“I am looking forward to using robotic technology in a clinical setting and I am honored to be part of this extraordinary group of colleagues.”
These three experts join Robocath’s existing MAB members: Dr. Alberto Cremonesi (Humanitas Gavazzeni Hospital - Bergamo BG, Italy), Pr. Alain Cribier (Emeritus Professor and TAVI founder, Rouen University Hospital - Rouen, France), Dr. Jean Fajadet (Pasteur Clinic – Toulouse, France), Pr. Eric Durand (Rouen University Hospital - Rouen, France), Pr. Rémi Sabatier (Caen University Hospital - Caen, France), Pr. Gregg Stone (Columbia University Hospital - New-York, United States).
Founded in 2009 by Philippe Bencteux, MD, Robocath designs, develops and commercializes robotic solutions to treat cardiovascular diseases. As an active player in the evolving medical robotic industry, these innovative solutions aim to make medical procedures safer, thanks to reliable technologies, while complementing manual interventions. R-One™ is the first solution developed by Robocath. It uses a unique technology that optimizes the safety of robotic-assisted coronary angioplasty. This medical procedure consists of revascularizing the cardiac muscle by inserting one or more implants (stents) into the arteries that supply it with blood. Every 30 seconds, somewhere in the world, this type of procedure is performed. R-One™ is designed to operate with precision and perform specific movements creating better interventional conditions. Thanks to its open architecture, R-One™ is compatible with market leading devices and cath labs. It received the CE marking in February 2019. Robocath aims to become the world leader in vascular robotics and develop the remote treatment of vascular emergencies, guaranteeing the best care pathway for all. Based in Rouen (France), Robocath has more than 25 employees.
“It’s an honour to join the medical advisory board of Robocath together with other world-renowned interventional cardiology experts. I’m convinced that robotics is definitely the future for our field. I’m looking forward to initiating clinical research and to sharing my experience worldwide.”